Top Industry Leaders in the Global Breast cancer Market
Genentech/Roche (US/Switzerland) Received FDA approval for Kadcyla® (trastuzumab emtansine) in September 2023 for the treatment of HER2-positive early breast cancer, offering a potential alternative to traditional chemotherapy.
AstraZeneca (UK) Announced positive Phase 3 trial results for Lynparza® (olaparib) in July 2023, demonstrating its efficacy in preventing the recurrence of breast cancer in BRCA-mutated patients.
Pfizer (US) Launched Ibrance® (palbociclib) in combination with Aromasin® (exemestane) in May 2023 for the treatment of postmenopausal women with HR-positive, HER2-negative advanced breast cancer, providing another treatment option for this specific group.
Verastem Oncology (US) Received Breakthrough Therapy Designation from the FDA for duvvaloran in June 2023 for the treatment of locally advanced or metastatic urothelial carcinoma, highlighting potential applications in other cancer types like breast cancer.
Illumina (US) Introduced the TruSight Oncology 500 next-generation sequencing (NGS) assay in October 2023, offering a comprehensive panel for detecting mutations in 523 cancer-related genes, including those relevant to breast cancer, facilitating personalized treatment decisions.
List of Breast Cancer Key Companies in the Market
- Mylan Laboratories
- AstraZeneca
- Celltrion
- Bristol-Myers Squibb
- FRESENIUS KABI
- Eisai Co. Ltd
- Baxter Healthcare Corporation
- GlaxoSmithKline
- Pfizer Inc.
- Halozyme Inc.